文献速递前列腺增生与排尿功能障碍男科与性医学

每日一次他达拉非5mg治疗≥75岁男性良性前列腺增生相关下尿路症状的疗效与安全性:跨国随机安慰剂对照临床研究汇总数据的整合分析

Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
PubMed 文献 · BJU Int · 2017-01-22

整合分析12项II-III期随机双盲和/或开放标签扩展研究,评估每日一次他达拉非5mg或安慰剂在<75岁与≥75岁良性前列腺增生相关下尿路症状(LUTS/BPH)男性中的短期疗效和短期及长期安全性。结果显示年龄与治疗交互作用P=0.034,他达拉非在≥75岁男性中未显著优于安慰剂,在<75岁组疗效显著。他达拉非安全性令人放心,未发现老年男性心血管不良事件增加。

要点

  • 他达拉非5mg每日一次在≥75岁LUTS/BPH男性中未显著优于安慰剂,在<75岁组疗效显著。
  • 短期他达拉非安全性:<75岁 vs ≥75岁,治疗中出现的不良事件33.8% vs 30.1%,导致停药的不良事件1.9% vs 3.0%。
  • ≥75岁组合并疾病更多、用药更多,可能降低疗效;样本量小限制混杂因素分析。

核心结论

  • 每日一次他达拉非5mg治疗LUTS/BPH的疗效在<75岁与≥75岁男性中存在差异,<75岁年龄组疗效显著。
  • 他达拉非安全性令人放心,未发现老年男性心血管不良事件增加。

研究设计与样本

  • 整合分析12项II-III期随机、双盲和/或开放标签扩展研究,评估短期(12-26周)疗效及短期和长期(42-52周)安全性。
  • 比较<75岁与≥75岁男性,所有男性接受每日一次他达拉非5mg或安慰剂。
  • 疗效指标为国际前列腺症状评分(IPSS),安全性指标包括治疗中出现的不良事件(TEAE)、导致停药的不良事件、严重不良事件(SAE)和心血管不良事件;所有分析均为意向性治疗。

主要发现

  • 平均IPSS变化在<75岁与≥75岁男性间存在显著差异(治疗×年龄交互作用P=0.034)。
  • 他达拉非在≥75岁男性中未统计学显著优于安慰剂,但效应量在不同研究间存在差异。
  • 各年龄组均观察到他达拉非疗效维持。
  • 短期他达拉非安全性:<75岁 vs ≥75岁,TEAE 52例(33.8%) vs 503例(30.1%),导致停药的不良事件3例(1.9%) vs 50例(3.0%),SAE 4例(2.6%) vs 15例(0.9%),心血管不良事件4例(2.6%) vs 30例(1.8%)。
  • 长期他达拉非安全性数据未显示年龄组间有临床相关差异。

关键数值与推荐

  • 他达拉非在<75岁男性中疗效显著,在≥75岁男性中未统计学显著优于安慰剂。
  • ≥75岁组合并疾病更多、用药更多,可能降低疗效。
  • 样本量小,无法进行单因素/多因素分析评估混杂因素的潜在干扰。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 排除有严重合并疾病的男性。
  • ≥75岁男性样本量有限。
  • ≥75岁组样本量小,无法进行单因素/多因素分析评估混杂因素的潜在干扰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess efficacy and safety of tadalafil in men aged ≥75 years with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) and additional safety in men aged ≥75 years with erectile dysfunction (ED). PATIENTS AND METHODS: We conducted an integrated analysis of 12 phase II-III randomized, double-blind and/or open-label extension studies to evaluate short-term (12-26 weeks) efficacy and short- and longer-term (42-52 weeks) safety in men aged <75 years vs men aged ≥75 years. All men received once-daily tadalafil 5 mg or placebo. The efficacy outcome was International Prostate Symptom Score (IPSS). Safety measurements included treatment-emergent adverse events (TEAEs), adverse events (AEs) leading to discontinuation, serious AEs (SAEs), and cardiovascular AEs. All analyses were intention-to-treat. Changes from baseline to efficacy endpoint and differences in changes between treatment groups were estimated as least-squares means using analysis of covariance models. RESULTS: Change in the mean IPSS was significantly different in men aged <75 years vs those aged ≥75 years across tadalafil and placebo groups (treatment-by-age interaction P = 0.034). Tadalafil was not statistically significantly better than placebo in men aged ≥75 years, but effect size varied between studies. Maintenance of efficacy with tadalafil was observed across age groups. Short-term tadalafil safety findings for men aged <75 vs ≥75 years included: TEAEs (52 [33.8%] vs 503 [30.1%]), AEs leading to discontinuation (3 [1.9%] vs 50 [3.0%]), SAEs (4 [2.6%] vs 15 [0.9%]) and cardiovascular AEs (4 [2.6%] vs 30 [1.8%]). Long-term tadalafil safety data did not reveal clinically relevant differences between age groups. Limitations include exclusion of men with serious co-existing conditions and limited sample sizes of men aged ≥75 years. CONCLUSIONS: Efficacy with once-daily tadalafil 5 mg in the treatment of LUTS/BPH differed between men aged <75 vs ≥75 years, with significant efficacy in the <75-year age group. The older age group had more concomitant diseases and used more drugs, which may have reduced efficacy. The small sample size precluded uni-/multivariate analyses to assess plausible interference from confounding factors. Tadalafil had a reassuring safety profile and no evidence of increased cardiovascular AEs in aging men.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Oelke M, Wagg A, Takita Y, et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. BJU Int. 2017. PMID: 27988986. doi:10.1111/bju.13744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。